Fredun Pharmaceuticals (BOM:539730) Cyclically Adjusted Book per Share: ₹62.70 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539730 Fredun Pharmaceuticals Ltd BOM:539730
67 GF Score
Price ₹955.20
GF Value ₹531.50
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Fredun Pharmaceuticals Cyclically Adjusted Book per Share?

Fredun Pharmaceuticals BOM:539730 -3.88% 67 Cyclically Adjusted Book per Share is ₹62.70 as of Mar. 2026. GuruFocus rates BOM:539730 with a GF Score™ of 67/100 and a GF Value™ of ₹531.50 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Fredun Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was ₹171.532. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹62.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fredun Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 30.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 29.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Fredun Pharmaceuticals was 29.30% per year. The lowest was 28.00% per year. And the median was 28.65% per year.

As of today (2026-07-18), Fredun Pharmaceuticals's current stock price is ₹955.20. Fredun Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₹62.70. Fredun Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 15.23.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fredun Pharmaceuticals was 17.48. The lowest was 4.55. And the median was 9.56.


Fredun Pharmaceuticals  (BOM:539730) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fredun Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=955.20/62.70
=15.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fredun Pharmaceuticals was 17.48. The lowest was 4.55. And the median was 9.56.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Fredun Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Fredun Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Fredun Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fredun Pharmaceuticals Cyclically Adjusted Book per Share Chart

Fredun Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.86 29.02 37.92 47.95 62.70

Fredun Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.95 0.00 53.88 0.00 62.70

BOM:539730 vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fredun Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fredun Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


BOM:539730
67GF Score
Fredun Pharmaceuticals Ltd BOM:539730
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fredun Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fredun Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=171.532/164.2724*164.2724
=171.532

Current CPI (Mar. 2026) = 164.2724.

Fredun Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 105.961 0.000
201609 10.125 105.961 15.697
201612 0.000 105.196 0.000
201703 6.745 105.196 10.533
201706 0.000 107.109 0.000
201709 19.005 109.021 28.637
201712 0.000 109.404 0.000
201803 21.570 109.786 32.275
201806 0.000 111.317 0.000
201809 30.494 115.142 43.506
201812 0.000 115.142 0.000
201903 32.575 118.202 45.271
201906 0.000 120.880 0.000
201909 33.503 123.175 44.681
201912 0.000 126.235 0.000
202003 34.524 124.705 45.478
202006 0.000 127.000 0.000
202009 35.024 130.118 44.217
202012 0.000 130.889 0.000
202103 35.985 131.771 44.861
202106 0.000 134.084 0.000
202109 38.682 135.847 46.776
202112 0.000 138.161 0.000
202203 51.181 138.822 60.564
202206 0.000 142.347 0.000
202209 55.564 144.661 63.097
202212 0.000 145.763 0.000
202303 70.880 146.865 79.281
202306 0.000 150.280 0.000
202309 79.265 151.492 85.952
202312 0.000 152.924 0.000
202403 86.168 153.035 92.496
202406 0.000 155.789 0.000
202409 92.390 157.882 96.129
202412 0.000 158.323 0.000
202503 99.811 157.552 104.069
202506 0.000 159.755 0.000
202509 97.682 162.289 98.876
202512 0.000 163.281 0.000
202603 171.532 164.272 171.532

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₹62.70 mean?
Fredun Pharmaceuticals (BOM:539730) has a Cyclically Adjusted Book per Share of ₹62.70 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Fredun Pharmaceuticals and its competitors.
Is Fredun Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Fredun Pharmaceuticals' current Cyclically Adjusted Book per Share is ₹62.70. Overall, Fredun Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Fredun Pharmaceuticals' Cyclically Adjusted Book per Share of ₹62.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Fredun Pharmaceuticals and its competitors. Fredun Pharmaceuticals's current Cyclically Adjusted Book per Share is ₹62.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹531.50, compared to a current price of ₹955.20 — trading 79.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is ₹62.70. Fredun Pharmaceuticals' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current Cyclically Adjusted Book per Share is ₹62.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?

Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued. The current stock price of ₹955.20 is trading 79.7% above its estimated GF Value™ of ₹531.50. GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:539730:

  • Cyclically Adjusted Book per Share: ₹62.70
  • GF Value™: ₹531.50 vs. price of ₹955.20 (79.7% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fredun Pharmaceuticals Business Description

Address Ganpatrao Kadam Marg, Delisle Road, 11th Floor, Urmi Estate 95, Lower Parel (West), Mumbai, MH, IND, 400013
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
67GF Score

Get the complete analysis for BOM:539730

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹955.20
Price
₹531.50
GF Value